<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">2979</id>
  <title>T3D2937</title>
  <common-name>Felbamate</common-name>
  <description>Felbamate is an anticonvulsant drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.</description>
  <cas>25451-15-4</cas>
  <pubchem-id>3331</pubchem-id>
  <chemical-formula>C11H14N2O4</chemical-formula>
  <weight>238.095360</weight>
  <appearance>White powder.</appearance>
  <melting-point>151.5°C</melting-point>
  <boiling-point nil="true"/>
  <density nil="true"/>
  <solubility>Slightly soluble in water</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Oral.  &gt;90%</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. &lt;i&gt;In vitro&lt;/i&gt; receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex. Antagonism of the NMDA receptor glycine binding site may block the effects of the excitatory amino acids and suppress seizure activity. Animal studies indicate that felbamate may increase the seizure threshold and may decrease seizure spread. It is also indicated that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding.</mechanism-of-toxicity>
  <metabolism>HepaticHalf Life: 20-23 hours</metabolism>
  <toxicity>LD50: 5000 mg/kg (Oral, Rat) (A308)</toxicity>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.</use-source>
  <min-risk-level nil="true"/>
  <health-effects>May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.</health-effects>
  <symptoms nil="true"/>
  <treatment>General supportive measures should be employed if overdosage occurs. It is not known if felbamate is dialyzable. (L1712)</treatment>
  <created-at type="dateTime">2009-07-21T20:28:00Z</created-at>
  <updated-at type="dateTime">2026-03-31T19:04:29Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Felbamate</wikipedia>
  <uniprot-id></uniprot-id>
  <kegg-compound-id>C07501</kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id>4995</chebi-id>
  <biocyc-id></biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id>Felbamate</stitch-id>
  <drugbank-id>DB00949</drugbank-id>
  <pdb-id></pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>NC(=O)OCC(COC(N)=O)C1=CC=CC=C1</moldb-smiles>
  <moldb-formula>C11H14N2O4</moldb-formula>
  <moldb-inchi>InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)</moldb-inchi>
  <moldb-inchikey>WKGXYQFOCVYPAC-UHFFFAOYSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">238.2399</moldb-average-mass>
  <moldb-mono-mass type="decimal">238.095356946</moldb-mono-mass>
  <origin>Exogenous</origin>
  <state>Solid</state>
  <logp>0.3</logp>
  <hmdb-id>HMDB15084</hmdb-id>
  <chembl-id>CHEMBL1094</chembl-id>
  <chemspider-id>3214</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference></synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM002308</chemdb-id>
  <dsstox-id>DTXSID9023041</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00010360</susdat-id>
  <iupac>3-(carbamoyloxy)-2-phenylpropyl carbamate</iupac>
</compound>
